Oramed appoints Dr. Daniel Aghion to board of directors effective Jan 1, 2024

ORAMED PHARMACEUTICALS INC.

Board size increased by one; Dr. Aghion fills resulting vacancy effective January 1, 2024.
Aghion is a neurosurgeon at Memorial Neuroscience Institute since 2016.
Compensation will match fees paid to other non-executive directors.
No arrangements or transactions requiring disclosure under Item 404(a) in connection with appointment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Daniel Aghion

director

ORMP · ORAMED PHARMACEUTICALS INC.

Effective: 2024-01-01
Filed: December 18, 2023, 6:59 PM ET

On December 18, 2023, Oramed Pharmaceuticals Inc. (the “Company”) increased the size of its Board of Directors (the “Board”) by one and appointed Dr. Daniel Aghion to serve as a director to fill the resulting vacancy, effective as of January 1, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Dr. Daniel Aghion was appointed as director at ORAMED PHARMACEUTICALS INC..

Action: appointed
Role: director

Exact text from the filing

On December 18, 2023, Oramed Pharmaceuticals Inc. (the “Company”) increased the size of its Board of Directors (the “Board”) by one and appointed Dr. Daniel Aghion to serve as a director to fill the resulting vacancy, effective as of January 1, 2024.

View on SEC.gov

ORAMED PHARMACEUTICALS INC. filing history →

Source: SEC EDGAR

accession 0001213900-23-096536

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.